- Home
- ORMP vs VCEL Comparison
ORMP vs VCEL Comparison
Compare ORMP & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORMP | VCEL |
|---|---|---|
| Founded | 2002 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.6M | 2.0B |
| IPO Year | N/A | 1997 |
Fundamental Metrics
Financial Performance| Metric | ORMP | VCEL |
|---|---|---|
| Price | $3.14 | $36.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $60.40 |
| AVG Volume (30 Days) | 272.7K | ★ 579.0K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 838.25 | 236.54 |
| EPS | ★ 1.03 | 0.25 |
| Revenue | $2,000,000.00 | ★ $258,716,999.00 |
| Revenue This Year | N/A | $17.86 |
| Revenue Next Year | N/A | $18.55 |
| P/E Ratio | ★ $2.96 | $148.17 |
| Revenue Growth | N/A | ★ 14.05 |
| 52 Week Low | $1.82 | $29.24 |
| 52 Week High | $3.19 | $63.00 |
Technical Indicators
Market Signals| Indicator | ORMP | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 74.34 | 45.31 |
| Support Level | $2.66 | $35.85 |
| Resistance Level | $2.84 | $42.68 |
| Average True Range (ATR) | 0.16 | 1.63 |
| MACD | 0.03 | -0.32 |
| Stochastic Oscillator | 80.89 | 12.60 |
Price Performance
Historical ComparisonAbout ORMP Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.